3 completed, 1 withdrawn. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 3, Withdrawn 1 |
Follow Hunter Syndrome: new trials by email Literature Review of Hunter Syndrome trials Research Report on Hunter Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) ELAPRASE, Rituximab, Methotrexate - Mucopolysaccharidosis (MPS), Hunter Syndrome | Phase 4 | Withdrawn | Takeda | 2023-02-28 | 2025-12-09 | |
| A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India Elaprase - Hunter Syndrome | Phase 4 | Completed | Takeda | 5 | 2022-04-21 | 2025-01-23 |
| Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Elaprase for intravenous (IV) infusion - Hunter Syndrome | Phase 4 | Completed | Shire | 21 | 2015-10-28 | 2026-04-02 |
| Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Idursulfase - Hunter Syndrome, Mucopolysaccharidosis II | Phase 4 | Completed | Shire | 28 | 2007-12-31 | 2021-06-08 |
Mucopolysaccharidosis II (4) · Lysosomal Storage Diseases (1) · Mucopolysaccharidoses (1) · Sudden Infant Death (1)
Carbohydrate Metabolism, Inborn Errors (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Connective Tissue Diseases (4) · Genetic Diseases, Inborn (4) · Genetic Diseases, X-Linked (4) · Heredodegenerative Disorders, Nervous System (4) · Intellectual Disability (4) · Metabolic Diseases (4) · Metabolism, Inborn Errors (4) · Mucinoses (4) · Nervous System Diseases (4) · Neurobehavioral Manifestations (4) · Neurologic Manifestations (4) · Nutritional and Metabolic Diseases (4) · Skin and Connective Tissue Diseases (4)
idursulfase (4) · Immunoglobulins, Intravenous (1) · Methotrexate (1) · Rituximab (1)
United States (2) · Brazil (1) · Dominican Republic (1) · Germany (1) · India (1) · Malaysia (1) · Philippines (1) · Poland (1) · Serbia (1) · Taiwan (1) · Thailand (1) · Vietnam (1)
2014 (1)